Short answer
NOVAVAX INC (NVAX) filed an 8-K current report with the SEC on October 29, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Novavax issued a press release on October 29, 2026, containing the company’s material disclosure.
NOVAVAX INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Novavax issued a press release on October 29, 2026, containing the company’s material disclosure
- Investors should review Exhibit 99.1 for the underlying announcement and its potential market impact
Item 8.01 · Other Events
- Sanofi dosed the fifth Phase 3 patient in its EU influenza-COVID-19 combination vaccine trial
- Milestone triggers $125 million payment to Novavax under the Sanofi collaboration
- Cash receipt anticipated by Q1 2027, providing meaningful near-term liquidity
- Payment depends on collaboration execution and clinical progress, with trial and regulatory risks remaining
Item EX-99.1 · Exhibit EX-99.1
- $125 million milestone earned as Sanofi initiates Phase 3 European trial of influenza-COVID-19 combination vaccine
- Trial evaluates Nuvaxovid with Sanofi’s high-dose flu vaccine in adults aged 60 and older
- Partnership has generated over $1 billion in Novavax revenue through October 2026
- Additional potential: $75 million manufacturing-transfer milestone anticipated mid-2027
- Further $225 million milestone contingent on successful U.S. launch and regulatory completion
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other NOVAVAX INC 8-K filings
Get the next NVAX 8-K as it lands
Follow NVAX for push alerts, or ask the research agent what this filing means.